--- title: Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours description: Duke Street Bio Ltd has announced that the first patient has been dosed in a Phase I trial evaluating the highly selective PARP1 inhibitor, DSB2455, in patients with solid tumours. image: https://news.lifesciencenewswire.com/hubfs/a18c113e-64be-4f5f-869b-6bbdb2feaade-upload_image_here-Duke-Street-Bio-Announces-First-Patient-Dosed-in-Phase.jpg --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-announces-first-patient-dosed-in-phase-i-trial-with-dsb2455-a-next-deneration-parp1-selective-inhibitor-for-the-treatment-of-solid-tumours) December 3, 2024 [![Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours](https://news.lifesciencenewswire.com/hs-fs/hubfs/a18c113e-64be-4f5f-869b-6bbdb2feaade-upload_image_here-Duke-Street-Bio-Announces-First-Patient-Dosed-in-Phase.jpg?width=560&height=294&name=a18c113e-64be-4f5f-869b-6bbdb2feaade-upload_image_here-Duke-Street-Bio-Announces-First-Patient-Dosed-in-Phase.jpg)](https://drive.google.com/file/d/1zdU9dv0Na1sAz8HLNqHome1L3JynqUQQ/view?usp=drive_link)Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first patient has been dosed in a Phase I trial evaluating the highly selective PARP1 inhibitor, DSB2455, in patients with solid tumours. DSB2455 is a potentially best-in-class, potent CNS penetrant PARP1 inhibitor with profound selectivity over the closely related enzyme PARP2. The Phase Ia/Ib trial is a multi-centre adaptively designed dose escalation study with expansion cohorts to assess the safety, tolerability, and activity of DSB2455 as monotherapy or in combination with anti-cancer agents in participants with advanced malignancies. First-generation non-selective PARP1/2 inhibitors have provided significant therapeutic benefit to patients whose tumours exhibit homologous repair (HR) deficiencies including BRCA mutations. However, their use has been associated with haematological toxicities that have restricted their application, particularly in combination with standard-of-care chemotherapy. *“Given that PARP2 is considered to drive haematoxicity, we believe that DSB2455 exhibits the optimal potency and selectivity profile to enhance efficacy and safety and may offer the potential to enable combination approaches with chemotherapy and radiotherapy”* said Dónal Landers, M.D., Ph.D., Chief Medical Officer at Duke Street Bio Ltd. About Duke Street Bio Ltd Duke Street Bio is a precision medicine biotech focused on exploiting tumour genetic vulnerabilities by developing the next generation of molecules targeting DNA Damage Repair (DDR) deficiencies in cancer. The company was founded by a highly experienced leadership team with a track record of developing best-in-class therapeutics and supported by a world class SAB. The company’s lead program, DSB2455, is a potentially best-in-class, potent CNS penetrant PARP1 inhibitor with profound selectivity over the closely related enzyme PARP2. For more information, please visit [www.dukestreetbio.com](http://www.dukestreetbio.com)  Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)